Clinical trial
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
NCT00055120 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00055120 |
|---|---|
| Title | When to Start Anti-HIV Drugs in Patients With Opportunistic Infections |
| Official title | A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections, AIDS-Related Opportunistic Infections |
| Intervention type | Drug |
| Interventions | Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine |
| Enrollment | 283 |
| Start date | Mar 1, 2003 |
| Primary completion | Sep 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Feb 20, 2003 |
| Last update posted | Oct 15, 2014 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: